The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with key programs in severe hypertriglyceridemia and HoFH advancing toward pivotal data and regulatory milestones. Dual-targeting siRNA innovation aims to address mixed hyperlipidemia and resi…
Guidance for FY 2026 is reaffirmed, with strong demand, robust order intake, and improving margins across all segments. Capacity expansions and disciplined execution support upgraded cash flow and profitability outlooks, while supply constraints and premium pricing persist.Based on Siemens Energy A…
The discussion highlighted the successful phase I-B results for PH-762, with an 85% response rate and strong safety profile. INTASYL's unique delivery and gene-targeting capabilities position it as a versatile platform for oncology and beyond, with the next trial planned for early next year.Based o…
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and equity plan amendments, all of which were approved by stockholders. A quorum was established, and final voting results will be filed with the SEC. Stockholders were invited to submit que…
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and an equity plan amendment, all of which were approved by stockholders. A quorum was established, and final voting results will be filed with the SEC.Based on Kairos Pharma, Ltd. [KAPA] AG…
Revenue and EBITDA saw strong growth in 2025, driven by acquisitions and a successful capital increase. The strategic plan targets over €160M in sales and €12M EBITDA by 2028, with a focus on both organic and inorganic growth. Recent acquisitions have diversified operations and strengthened financi…
A robust RNAi cardiometabolic pipeline is advancing, with plozasiran showing sustained triglyceride reductions and a strong safety profile, zodasiran demonstrating durable LDL-C lowering in HoFH, and ARO-DIMER-PA targeting dual lipid pathways. Key data readouts and regulatory filings are expected i…
NGN-401 gene therapy for Rett syndrome showed 100% of phase I/II participants gained developmental milestones, with rapid, durable, and multi-domain improvements sustained up to 30 months. The therapy was well tolerated, exceeded efficacy thresholds, and is on track for regulatory submission and co…
Earnings and revenue grew for the eighth consecutive year, with headline EPS up 9.1% and revenue rising 7.7% to R2.84 billion. Strong international manufacturing performance and prudent capital allocation, including share buybacks, underpin a positive outlook.Original document: Argent Industrial Li…
Revenue and EBITDA surged, driven by ecosystem expansion beyond food delivery, with adjacencies like grocery, pharmacy, fintech, and ads growing rapidly. Despite competitive pressures in Brazil and ongoing investments in Europe and India, the company maintains strong cash flow, robust share buyback…
Significant advances were presented in individualized neoantigen vaccines, with TG4050 progressing in head and neck cancer and TG4070 launching in non-small cell lung cancer. Manufacturing is transitioning to a scalable cell line process, and the SNIPER platform is validated for future indications…
The AGM highlighted strong financial discipline, strategic growth plans through 2029, and robust digital and AI-driven initiatives in both media and education. All proposals, including board changes, remuneration policies, and a share counter split, were approved with overwhelming shareholder suppo…
The acquisition of Theravance Biopharma adds a durable, cash-generative COPD asset, YUPELRI, and multiple value streams to the portfolio, funded through non-recourse financing and expected to be accretive post-closing. Integration will focus on cost synergies and leveraging existing infrastructure…
Restated 2024 results reflect compliance investigations and asset impairments, with 2025 revenue up mainly from Bormioli acquisition but organic growth flat. Guidance for 2026 is cautious due to economic headwinds, with margin improvement expected from transformation initiatives and key focus on Ce…
NGN-401 gene therapy for Rett syndrome showed rapid, durable, and multi-domain developmental gains in all phase I/II participants, with 80% meeting the primary endpoint at 12 months and no milestones lost up to 30 months. The therapy was well tolerated, and robust long-term data support its potenti…
The meeting confirmed quorum, approved all resolutions including director elections, auditor appointment, share consolidation, and bylaw amendments. No shareholder questions were raised, and management noted ongoing initiatives with updates to follow.Based on DeFi Technologies Inc [DEFI] AGM 2026 A…
Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week regimen. Launch targets a $2B market with a focused commercial strategy, broad payer access expected in 6–9 months, and a robust patient su…
Issued senior secured US dollar bonds to fund lending growth, maintaining strong asset quality and profitability. AUM grew 53% CAGR to ₹366bn, with gold loans as the largest segment and a robust branch network. Advanced technology, diversified funding, and strong governance underpin continued expan…
Revenue declined 16.3% year-over-year to RMB2,319.0 million, with profit attributable to owners down 71.7% to RMB85.4 million and gross margin falling to 20.3%. Trading remains suspended amid ongoing investigations and auditor changes, while management expects operational improvements in the second…
The acquisition of a leading U.S. real estate platform adds GBP 22 billion AUM, diversifies the group’s product suite, and is expected to be highly accretive, with significant cross-sell and growth opportunities. The deal is strategically timed, balances AUM across geographies, and positions the gr…
